Adlai Nortye's Key Cancer Drug Progresses to Phase III Adlai Nortye's lead cancer therapy, AN2025, has entered Phase III trials targeting advanced head and neck cancers. The company is also advancing other treatments, including AN0025 for lung and breast cancers, and AN4005 for PD-L1 disruption, reflecting a robust pipeline in oncology innovation.12